This is the homepage of the Medarus, the company behind the MRS-Brenda, CIN III, EndoCa guideline and EndoEnzian App. They all have been created as a ‚hobby‘ and helper for my clinical daily routine. They are published because I am happy to share them and help other clinicians to improve their patient care. My first attempt was MRS-BRENDA. An application that enables you to quickly calculate the BRENDA Metastatic Recurrence Score for breast cancer patients.
The score has been published in 2021 in Cancers here
Simple Summary: The BRENDA-Score provides an easy to use tool for clinicians to estimate the
risk of recurrence in primary breast cancer. The algorithm has been validated via a second
independent database and provides five recurrence risk groups. This grouping helps clinicians to
encourage high risk patients to undergo the recommended treatment….
BRENDA-Score, a Highly Significant, Internally and Externally
Validated Prognostic Marker for Metastatic Recurrence:
Analysis of 10,449 Primary Breast Cancer Patients, Wischnewsky et al. Cancers 2021
… further:
…Our model seems to be superior to the NPI (Nottingham Prognostic Index) for risk of recurrence in distant organs….
BRENDA-Score, a Highly Significant, Internally and Externally
Validated Prognostic Marker for Metastatic Recurrence:
Analysis of 10,449 Primary Breast Cancer Patients, Wischnewsky et al. Cancers 2021
Like any tool it is only as good as the user. The app (MRS BRENDA II) ensures an easy implementation of the Brenda score in clinical routine.
This was followed by the legal obligation in Germany to submit – even precancerous – leasions to a tumor data base. Unfortunately my clinic software always wanted ALL details needed for the cancerous dataset for my precancerous too. After a while this was to annoying and I set up the CIN APP. This only collects the bare minimum from the surgeon and can submit it to the tumor data base via an oBDS format. Currently I try to get it certified but as with any ‚hobby‘ time is short and requested changes to the code take longer as I want (plus I still only want to submit the bare minimum – which is probably not the focus of the tumor data base).
And last but not least the EndoEnzian App. I must admit I missed the official SEF app development otherwise I wouldn’t have published this one. But as I spent some time programming and even implemented the rASRM- and EFI-score it may as well just be out in the app store. The aim is to improve the patient reports and ultimately their care hopefully this little contribution helps.